This segment focuses on the research, development, and clinical evaluation of DKN-01, a humanized monoclonal antibody targeting Dickkopf-related protein 1 (DKK1). DKN-01 is being investigated in multiple clinical trials across various cancer types, including esophagogastric cancer, hepatobiliary cancer, gynecologic cancers, and prostate cancer. The R&D activities include preclinical studies, clinical trial design and execution, biomarker analysis, and regulatory submissions. Technologies employed include antibody engineering, immuno-oncology, and various diagnostic assays. The primary therapeutic focus is on improving outcomes for patients with difficult-to-treat cancers. Patient impact is addressed through the potential for improved survival rates and quality of life. Market positioning involves targeting unmet medical needs in oncology, with a competitive advantage in the development of novel immuno-oncology therapies. Future opportunities include expanding the clinical development program and exploring combination therapies. Regulatory and clinical aspects involve adherence to FDA guidelines and collaboration with clinical research organizations. Partnerships with research institutions and pharmaceutical companies are crucial for advancing the development of DKN-01.

This segment is dedicated to the research and development of Sirexatamab, a humanized monoclonal antibody. The R&D activities include preclinical studies, clinical trial design and execution, biomarker analysis, and regulatory submissions. Technologies employed include antibody engineering, immuno-oncology, and various diagnostic assays. The primary therapeutic focus is on improving outcomes for patients with difficult-to-treat cancers. Patient impact is addressed through the potential for improved survival rates and quality of life. Market positioning involves targeting unmet medical needs in oncology, with a competitive advantage in the development of novel immuno-oncology therapies. Future opportunities include expanding the clinical development program and exploring combination therapies. Regulatory and clinical aspects involve adherence to FDA guidelines and collaboration with clinical research organizations. Partnerships with research institutions and pharmaceutical companies are crucial for advancing the development of Sirexatamab.